Jump to main content

CEO Paul Perreault highly satisfied with developments in Marburg

On 26 and 27 October 2021, Paul Perreault, CEO of CSL Limited was welcomed to the Marburg site.

Group of people at construction site

CEO Paul Perreault, Mike Deem, Head of Global Manufacturing & Supply Chain, and Aymeric Ange, Chief of Staff to the CEO, had the new buildings under construction and new production facilities to be implemented in their sights in particular: at the site in Goerzhausen – and thus with close proximity to world-class universities and other leading biotechnology companies for innovative ways of collaboration – a new research and development center is currently being built for CSL Behring Innovation GmbH, the “R&D Campus”, and a state-of-the-art administration building for CSL Behring GmbH, the “Office of the Future”. The guests also toured the new basic fractionation building with its optimized process flows, modern technologies and increased level of automation. This is where the first basic physical-biochemical processes take place to produce life-saving and life-sustaining drugs from frozen human plasma through further production steps.

CEO Paul Perreault was very impressed by the commitment of the teams on site: “The continuing developments since my last visit to Marburg are inspiring. The Marburg site is critically important within the global CSL network. I have seen how the teams are collaborating on advancing innovation and ensuring a safe, reliable supply of our medicines for patients. I want to thank all of our Marburg colleagues for their contributions and delivering on their promise."